ISPO

Cancer Detection and Prevention Volume 27 / Issue 2 (Mar-Apr 2003)

Table of Contents and Editor's Notes

The peer review process occasionally results in approval of controversial publications that do not necessarily reflect the viewpoint of the editors. Readers of the journal are encouraged to critically review and comment on presented data by submitting a "Letter to the Editor" that may be reprinted in a subsequent issue.

Epidemiology of pancreatic cancera: an overview

P Ghadirian PhD, HT Lynch MD, D Krewski PhD

Increased risks of pancreatic carcinoma are associated with diabetes, history of pancreatitis, pernicious anemia, partial gastrectomy, cholecystectomy, familial adenomatous polyposis and breast cancer families with BRCA 1 and 2 mutations. A positive association exists for fat oil meat fried foods cholesterol and salt. Cigarette smoking has shown the strongest positive association while alcohol consumption has not been correlated with pancreatic cancer risk. >>>

Molecular epidemiology of plasma oncoproteins in vinyl chloride monomer workers in Taiwan

JCJ Luo, MD, TJ Cheng, MD, CL Du, MD, JD Wang, MD

Ten percent of 251 vinyl chloride monomere (VCM) workers in Taiwan were positive for Asp13-21-Ki-ras plasma oncoprotein compared to none of 36 controls. Over expression of p53 was found in 13.2% of VCM workers and 5.6% of controls. >>>

Skin tumor promotion by Vitamin E in mice: amplification by ionizing radiation and Vitamin C

REJ Mitchel, PhD, RA McCann, ACT

Application of Vitamin C amplified the papilloma tumor-promoting action of Vitamin E in DMBA initiated mouse skin and shortened the tumor latent period. >>>

Immunohistochemical demonstration of the gamma2 chain of lamini-5 in urinary bladder urothelial carcinoma: Impact for diagnosis and prognosis

W Hindermann, MD, A Berndt, PhD, KM Haas, MD, H Wunderlich, MD, D Katenkamp, MD, H Kosmehl, MD

Immunohistochemical staining of invasive papillary urothelial carcinoma revealed stromal deposition and cellular retention of the laminin-5 gamma 2 chain associated with basement membrane breaks. In non-neoplastic urothelial mucosa the laminin-5 gamma 2 chain was exclusively restricted to the basement membrane region. Non-invasive tumors had only minor alterations. >>>

Reliability of serum iron, ferritin, nitrite, and association with risk of renal cancer in women

MA Ali, PhD, A Akhmedkhanov, MD, A Zeleniuch-Jaquotte, MD, P Toniolo, MD, K Frenkel, PhD, X Huang, PhD.

In serum samples obtained before clinical manifestation of disease levels of iron, ferritin and nitrite were associated with a decreased risk of renal cell carcinoma. >>>

Daily variations of plasma malondialdehyde levels in patients with early breast cancer

H Akbulut, MD, KG Akbulut, F Icli, A Büyükcelik

The plasma malondialdehydade (MDA) levels of patients with early breast cancer revealed significant diurnal variations with the highest levels at 20:00h and the lowest at 04:00h. At 20:00h the plasma MDA levels and the daily average levels of the controls were significantly lower than those in the patient group. >>>

Detection of serum p53 protein in patients with different gastrointestinal cancers

AM Attallah, PhD, MM Abdel-Aziz, PhD, AM El-Sayed, MSc, AA Tabll, PhD

In 69% of 158 gastrointestinal patients the preoperative serum p53 concentrations were highly elevated compared to controls. No significant difference in serum p53 concentrations was found between different gastrointestinal cancer with the exception of p53 in 100% of cholangiocarcinomas. >>>

Common genetic variants fo TP53 and BRCA2 in esophogeal cancer patients and healthy individuals from low and high risk areas of northern China

N Hu MD, PhD, WJ Li MD, H Su, PhD, C Wang, BS, AM Goldstein, PhD, PS Albert, PhD, MR Emmert-Buck, MD, PhD, LH Kong, BS, MJ Roth, MD, SM Dawsey, MD, LJ He, MD, SF Cao, BS, T Ding, MD, C Giffen, DVM, PR Taylor, MD, ScD

Polymorphisms in the TP53 and BRCA2 were determined in healthy individuals from Chinese low and high risk areas and compared to patients with esophageal squamous cell carcinoma (ESCC). Distribution of genotypes differed between the low risk group and the ESCC cases. There was no significant difference between the high risk groups and patients with ESCC. >>>

Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma

AG Casson, FRCSC, Z Zheng, MD, D Chiasson, BSc, K MacDonald, BSc, DC Riddell, MD, JR Guernsey, PhD, DL Guernsey, PhD, J McLaughlin, MD

Surgically resected esophageal adenocarcinomas were genotyped for cytochrome P450 (CYP), microsomal epoxide hydroxylase (mEH), glutathione-S-transferase (GST) T1, M1, P1. In patients without preoperative chemo- or radiation therapy esophageal adenocarcinoma was not associated with GST T1 and M1 and cytochrome p450. Polymorphisms of GST P1 and mEH were implicated in susceptibility to adenocarcinoma. >>>

Association of cellular apoptosis with anti-tumor effects of the Chinese herbal complex in chemo-endocrine resistant endometrial cancer cell line

Z Lian, MD, PhD, K Niwa, MD, PhD, J Gao, MD, K Tagami, MD, H Mori, MD, PhD, T Tamaya, MD, PhD

A special Chinese herbal complex inhibited completely the proliferation of endocrine-resistant (AN3CA) cells during a 7-day culture period and induced cell apoptosis after 48 h treatment. The herbal complex suppressed levels of c-myc and bcl-2 proteins in AN3CA cells. >>>

The antitumor effect of the somatostatin analog TT-232 depends on the treatment regimen

M Tejeda, PhD, D Gaál, PhD, O Csuka, PhD, A Ullrich, DSc, R Schwab, MD, Á Pap, DSc, A Horváth, PhD, G Kéri, DSc

Use of the somatostatin analogue TT-232 with effects on tyrosine kinase inhibition and apoptosis induction resulted in 77 to 100 percent tumor growth inhibition and 40 to 60 percent tumor-free survival of mice with S-180 sarcoma transplanted tumors. Treatment with TT-232 started one day after transplantation produced a 77 to 80 percent growth inhibition. Administration of TT-232 after development of tumors was associated with a 61 percent tumor inhibitory effect. >>>

 

Herbert E. Nieburgs, MD
Worcester, MA
2003